Frontline plc.
FRO – 2025 Annual General Meeting
FRO – 2025 Annual General Meeting
Frontline plc (the “Company”) advises that the 2025 Annual General Meeting of the Shareholders of the Company was held on 8 December 2025 at 09:00 a.m. at Metis Tower, 28th October Avenue and Iakovou Tombazi Street, 4th floor, 3107 Limassol, Cyprus. The audited consolidated financial statements for the Company for the year ended 31 December 2024 were presented to the Meeting.
In addition, the following resolutions were passed:
- To re-elect John Fredriksen as a Director of the Company.
- To re-elect James O’Shaughnessy as a Director of the Company.
- To re-elect Ola Lorentzon as a Director of the Company.
- To re-elect Cato Stonex as a Director of the Company.
- To re-elect Ørjan Svanevik as a Director of the Company.
- To re-elect Dr. Maria Papakokkinou as a Director of the Company
- To elect Richard C. Prince as a Director of the Company.
- To re-appoint PricewaterhouseCoopers of Limassol, Cyprus as auditors and to authorise the Directors to determine their remuneration.
- To approve the remuneration of the Company’s Board of Directors of a total amount of fees not to exceed USD 600,000 for the year ended December 31, 2025.
- To approve with effect from 12:00 p.m. (Cyprus time) on 08th December, 2025 (the “Effective Date”) and for a period of twelve (12) calendar months from the Effective Date the exclusion of the shareholders’ right of pre-emption with respect to any offer by the Company to the public against cash consideration, as may be decided by the Board of Directors from time to time, of a maximum of 377,377,111 ordinary shares of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company at a subscription price which shall be determined by the Board of Directors not lower than USD 1 per share.
- To approve with effect from 12:00 pm (Cyprus time) on 08th December, 2025 (the “Effective Date”) and for a period of twelve (12) calendar months from the Effective Date the exclusion of the shareholders’ right of pre-emption with respect to any offer by the Company to the public for cash consideration as may be decided by the Board of Directors from time to time, of a maximum of 377,377,111 debentures or other securities convertible into ordinary shares of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company or options or other securities carrying the right to subscribe for ordinary shares of the Company of nominal value USD 1 each ranking pari passu with the existing ordinary shares of the Company at a subscription price which shall be determined by the Board of Directors not lower than USD 1 per security.
- To approve on an advisory vote basis the Company’s Remuneration Report for the year ended December 31st, 2024 pursuant to the provisions of the Encouragement of Long-Term Shareholders Engagement Law 111(I)/2021.
8 December 2025
The Board of Directors
Frontline plc
Limassol, Cyprus
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Rias A/S10.12.2025 16:52:33 CET | Press release
Annual Report 2024/25 RIAS A/S
MT Højgaard Holding A/S10.12.2025 16:42:27 CET | Pressemeddelelse
MT Højgaard Holding A/S: Kim Thinggaard tiltræder som administrerende direktør i Enemærke & Petersen
MT Højgaard Holding A/S10.12.2025 16:42:27 CET | Press release
MT Højgaard Holding A/S: Kim Thinggaard joins Enemærke & Petersen as CEO
Heineken10.12.2025 15:32:41 CET | Press release
Heineken® Launches New WhatsApp Technology That Swaps Voice Notes for Real Life Conversations Over a Beer
Rapala VMC Oyj10.12.2025 15:30:00 CET | Press release
Rapala VMC Corporation adds Q1 and Q3 business reviews to its financial reporting in 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom